Analysts forecast that CareDx Inc (NASDAQ:CDNA) will announce sales of $12.09 million for the current quarter, Zacks reports. Two analysts have provided estimates for CareDx’s earnings. The highest sales estimate is $12.40 million and the lowest is $11.77 million. CareDx reported sales of $10.86 million during the same quarter last year, which would suggest a positive year over year growth rate of 11.3%. The firm is expected to report its next earnings results after the market closes on Thursday, March 22nd.
On average, analysts expect that CareDx will report full year sales of $12.09 million for the current fiscal year, with estimates ranging from $47.59 million to $48.20 million. For the next fiscal year, analysts anticipate that the firm will report sales of $61.33 million per share, with estimates ranging from $59.80 million to $62.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover CareDx.
A number of research firms recently issued reports on CDNA. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine cut CareDx from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Finally, HC Wainwright initiated coverage on CareDx in a research report on Monday, November 27th. They issued a “buy” rating and a $12.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $8.65.
Shares of CareDx (NASDAQ CDNA) opened at $5.75 on Wednesday. The stock has a market capitalization of $166.19, a price-to-earnings ratio of -3.18 and a beta of 0.72. CareDx has a 12-month low of $0.76 and a 12-month high of $7.98. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.